MicroRNA: A prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy

Journal of Biomedical Science

Volumn 20, Issue 1, 2013, Pages

  To, Kenneth K W ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

3 untranslated region; ATP binding cassette transporters; microRNA; Multidrug resistance; Non coding RNAs; Prognostic biomarkers

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEFITINIB; GEMCITABINE; MICRORNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 6; PACLITAXEL; TEMOZOLOMIDE; UNTRANSLATED RNA; ABC TRANSPORTER;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; GENETIC POLYMORPHISM; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BIOMARKERS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS; NEOPLASMS;

MLCS; MLOWN;

EID: 84890534196     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-20-99     Document Type: Article

References (133)

1. Multidrug resistance: can new drugs help chemotherapy score against cancer? Goldman B, J Natl Cancer Inst 2003 95 255 257 10.1093/jnci/95.4.255 12591977 (Pubitemid 36336473)
2. Multidrug resistance in cancer: role of ATP-dependent transporters. Gottesman MM, Fojo T, Bates SE, Nat Rev Cancer 2002 2 48 58 10.1038/nrc706 11902585 (Pubitemid 37328807)
3. MicroRNAs: target recognition and regulatory functions. Bartel DP, Cell 2009 136 215 233 10.1016/j.cell.2009.01.002 19167326
4. Vertebrate microRNA genes. Lim LP, Glasner ME, Yekta S, Burge CB, Bartel DP, Science 2003 299 1540 10.1126/science.1080372 12624257 (Pubitemid 36297696)
5. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Lewis BP, Burge CB, Bartel DP, Cell 2005 120 15 20 10.1016/j.cell.2004.12.035 15652477 (Pubitemid 40094598)
6. Systematic discovery of regulation motifs in human promoters and 3′UTRs by comparison of several mammals. Xie X, Lu J, Kulbokas EJ, et al. Nature 2005 434 338 345 10.1038/nature03441 15735639 (Pubitemid 40469170)
7. MicroRNA expression profiles classify human cancers. Lu J, Getz G, Miska EA, et al. Nature 2005 435 834 838 10.1038/nature03702 15944708 (Pubitemid 40839735)
8. Oncomirs-microRNAs with a role in cancer. Esquela-Kerscher A, Slack FJ, Nat Rev Cancer 2006 6 259 269 10.1038/nrc1840 16557279
9. MicroRNAs as tumor suppressors. Hammond SM, Nat Genet 2007 39 582 583 17460676 (Pubitemid 46676097)
10. MicroRNA: potential for cancer detection, diagnosis, and prognosis. Tricoli JV, Jacobson JW, Cancer Res 2007 67 4553 4555 10.1158/0008-5472.CAN-07- 0563 17510380 (Pubitemid 46910157)
11. miRNAs in cancer: approaches, aetiology, diagnostics and therapy. Blenkiron C, Miska EA, Hum Mol Genet 2007 16 106 R113 10.1093/hmg/ddm056 17613543 (Pubitemid 47241849)
12. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Fojo T, Drug Resist Update 2007 10 59 67 10.1016/j.drup.2007.02.002 (Pubitemid 46656478)
13. MicroRNAs modulate the chemosensitivity of tumor cells. Blower PE, Chung JH, Verducci JS, et al. Mol Cancer Ther 2008 7 1 9 10.1158/1535-7163.MCT-07-0573 18187804
14. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Kovalchuk O, Fikowski J, Meservy J, et al. Mol Cancer Ther 2008 7 2152 2159 10.1158/1535-7163.MCT-08-0021 18645025
15. MicroRNA expression profiles for the NCI-60 cancer cell line panel. Blower PE, Verducci JS, Lin S, et al. Mol Cancer Ther 2007 6 1483 1491 10.1158/1535-7163.MCT-07-0009 17483436 (Pubitemid 46954015)
16. Regulation of ABCG2 expression at the 3′untranslated region of its mRNA through modulation of transcript stability and protein translation by a putative microRNA in the S1 colon cancer cell line. To KK, Zhan Z, Litman T, Bates SE, Mol Cell Biol 2008 28 5147 5161 10.1128/MCB.00331-08 18573883
17. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2. To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE, Mol Cancer Ther 2009 8 2959 2968 10.1158/1535-7163.MCT-09-0292 19825807
18. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Pan YZ, Morris ME, Yu AM, Mol Pharmacol 2009 75 1374 1379 10.1124/mol.108.054163 19270061
19. MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Xia L, Zhang D, Du R, et al. Int J Cancer 2008 123 372 379 10.1002/ijc.23501 18449891 (Pubitemid 351842022)
20. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Mishra PJ, Humeniuk R, Longo Sorbello GS, Banerjee D, Bertino JR, Proc Natl Acad Sci USA 2007 104 13513 13518 10.1073/pnas.0706217104 17686970 (Pubitemid 47293976)
21. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Yang H, Kong W, He L, et al. Cancer Res 2008 68 425 433 10.1158/0008-5472.CAN-07-2488 18199536 (Pubitemid 351380068)
22. Resistance may not be futile: microRNA biomarkers for chemoresisatnce and potential therapeutics. Allen KE, Weiss GJ, Mol Cancer Ther 2010 9 3126 3136 10.1158/1535-7163.MCT-10-0397 20940321
23. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Li Z, Hu S, Wang J, et al. Gynecol Oncol 2010 119 125 130 10.1016/j.ygyno.2010.06.004 20624637
24. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Zhu H, Wu H, Liu X, et al. Biochem Pharmacol 2008 76 582 588 10.1016/j.bcp.2008.06.007 18619946
25. MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest. Xu Y, Xia F, Ma L, et al. Cancer Lett 2011 310 160 169 21802841
26. The prognostic and chemotherapeutic value of miR-296 in esophageal squamous cell carcinoma. Hong L, Han Y, Zhang H, et al. Ann Surg 2010 251 1056 1063 10.1097/SLA.0b013e3181dd4ea9 20485139
27. Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S, Am J Pathol 2012 180 2490 2503 10.1016/j.ajpath. 2012.02.024 22521303
28. Let-7 modulates required resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Boyerinas B, Park SM, Murmann AE, et al. Int J Cancer 2012 130 1787 1797 10.1002/ijc.26190 21618519
29. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Liang Z, Wu H, Xia J, et al. Biochem Pharmacol 2010 79 817 824 10.1016/j.bcp.2009.10.017 19883630
30. Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1. Pan YZ, Zhou A, Hu Z, Yu AM, Drug Metab Dispos 2013 doi: 10.1124/dmd.113.052092
31. MiR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2. Xu K, Liang X, Shen K, et al. Biochem J 2012 446 291 300 10.1042/BJ20120386 22676135
32. ID4 imparts chemoresistance and cancer stemness to glioma cells by derepressing miR-9*-mediated suppression of SOX2. Jeon HM, Sohn YW, Oh SY, et al. Cancer Res 2011 71 3410 3421 10.1158/0008-5472.CAN-10-3340 21531766
33. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I, Pharmacogenet Genomics 2012 22 198 205 10.1097/FPC.0b013e328350012b 22241070
34. MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Xu XT, Xu Q, Tong JL, et al. Br J Cancer 2012 106 1320 1330 10.1038/bjc.2012.88 22453125
35. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c, -520 h) and their differential expression in stem-like ABCG2+ cancer cells. Pan YZ, Seigel GM, Hu ZH, Huang M, Yu AM, Biochem Pharmacol 2011 81 783 792 10.1016/j.bcp.2010.12.018 21219875
36. MicroRNAs play a role in the development of human hematopoietic stem cells. Liao R, Sun J, Zhang L, et al. J Cell Biochem 2008 104 805 817 10.1002/jcb.21668 18189265 (Pubitemid 351830831)
37. hsa-miR-520 h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations. Wang F, Xue X, Wei J, et al. Br J Cancer 2010 103 567 574 10.1038/sj.bjc.6605724 20628378
38. MiR-181a enahances drug sensitivity in mitoxantrone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2). Jiao X, Zhao L, Ma M, Bai X, He M, Yan Y, Wang Y, Chen Q, Zhao X, Zhou M, Cui Z, Zheng Z, Wang E, Wei M, Breast Cancer Res Treat 2013 139 717 730 10.1007/s10549-013- 2607-x 23780685
39. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Ma MT, He M, Wang Y, Jiao XY, Zhao L, Bai XF, Yu ZJ, Wu HZ, Sun ML, Song ZG, Wei MJ, Cancer Lett 2013 339 107 115 10.1016/j.canlet.2013.07.016 23879965
40. miR-1915 inhibits Bcl-2 to moderate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells. Xu K, Liang X, Cui D, Wu Y, Shi W, Liu J, Mol Carcinog 2013 52 70 78 22121083
41. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostat cancer PC3 cells through direct and indirect mechanisms. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M, Prostate 2010 70 1501 1512 10.1002/pros.21185 20687223
42. miR-200c inhibits melanoma progression and drug resistance through down-regulation of Bmi-1. Liu S, Tetzlaff MT, Cui R, Xu X, Am J Pathol 2012 181 1823 1835 10.1016/j.ajpath.2012.07.009 22982443
43. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Puhr M, Hoefer J, Schafer G, et al. Am J Pathol 2012 181 2188 2201 10.1016/j.ajpath.2012.08.011 23041061
44. MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents. Cochrane DR, Spoelstra NS, Howe EN, Nordeen SK, Richer JK, Mol Cancer Ther 2009 8 1055 1066 10.1158/1535-7163. MCT-08-1046 19435871
45. ABCG2: determining its relevance in clinical drug resistance. Robey RW, Polgar O, Deeken J, To KW, Bates SE, Cancer Metastasis Rev 2007 26 39 57 10.1007/s10555-007-9042-6 17323127 (Pubitemid 46452182)
46. Amplification of 4q21-q22 and the MXR gene in independently derived mitoxantrone-resistant cell lines. Knutsen T, Rao VK, Ried T, et al. Genes Chromosomes Cancer 2000 27 110 116 10.1002/(SICI)1098-2264(200001)27:1<110:: AID-GCC14>3.0.CO;2-4 10564593
47. Novel 5′untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage. Nakanishi T, Bailey-Dell KJ, Hassel BA, et al. Cancer Res 2006 66 5007 5011 10.1158/0008-5472.CAN-05-4572 16707421 (Pubitemid 43844920)
48. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. Krishnamurthy P, Ross DD, Nakanishi T, et al. J Biol Chem 2004 279 24218 24225 10.1074/jbc.M313599200 15044468 (Pubitemid 38725283)
49. Regulation of mRNA stability in mammalian cells. Guhaniyogi J, Brewer G, Gene 2001 265 11 23 10.1016/S0378-1119(01)00350-X 11255003 (Pubitemid 32209246)
50. Mechanisms and consequences of alternative polyadenylation. Di Giammartino DC, Nishida K, Manley JL, Mol Cell 2011 43 853 866 10.1016/j.molcel.2011.08.017 21925375
51. A large-scale analysis of mRNA polyadenylation of human and mouse genes. Tian B, Hu J, Zhang H, Lutz CS, Nucleic Acids Res 2005 33 201 212 10.1093/nar/gki158 15647503 (Pubitemid 40276942)
52. Proliferating cells express mRNAs with shortened 3′untranslated regions and fewer microRNA target sites. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB, Science 2008 320 1643 1647 10.1126/science.1155390 18566288 (Pubitemid 351931255)
53. Reprogramming of 3′untranslated regions of mRNAs by alternative polyadenylation in generation of pluripotent stem cells from different cell types. Ji Z, Tian B, PLoS One 2009 4 8419 10.1371/journal.pone.0008419 20037631
54. Widespread shortening of 3′UTR by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Mayr C, Bartel DP, Cell 2009 138 673 684 10.1016/j.cell.2009.06.016 19703394
55. Complex and dynamic landscape of RNA polyadenylation revealed by PAS-Seq. Shepard PJ, Choi EA, Lu J, Flanagan LA, Hertel KJ, Shi Y, RNA 2011 17 761 772 10.1261/rna.2581711 21343387
56. Differential repression of alternative transcripts: a screen for miRNA targets. Legendre M, Ritchie W, Lopez F, Gautheret D, PLoS Comput Biol 2006 2 43 10.1371/journal.pcbi.0020043 16699595 (Pubitemid 43794327)
57. High level functional expression of the ABCG2 multidrug transporter in undifferentiated human embryonic stem cells. Apati A, Orban TI, Varga N, et al. Biochim Biophys Acta 2008 1778 2700 2709 10.1016/j.bbamem.2008.08.010 18793608
58. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Juliano RL, Ling V, Biochim Biophys Acta 1976 455 152 162 10.1016/0005-2736(76)90160-7 990323
59. P-glycoprotein: from genomics to mechanism. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM, Oncogene 2003 22 7468 7485 10.1038/sj.onc.1206948 14576852 (Pubitemid 37487170)
60. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Zhou SF, Wang LL, Di YM, et al. Curr Med Chem 2008 15 1981 2039 10.2174/092986708785132870 18691054
61. CRD-BP shields c-myc and MDR-1 RNA from endonucleolytic attack by a mammalian endoribonuclease. Sparanese D, Lee CH, Nucleic Acids Res 2007 35 1209 1221 10.1093/nar/gkl1148 17264115 (Pubitemid 46522973)
62. Identification of let-7-regulated oncofetal genes. Boyerinas B, Park SM, Shomron N, et al. Cancer Res 2008 68 2587 2591 10.1158/0008-5472.CAN-08-0264 18413726 (Pubitemid 351556256)
63. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis. Nardinocchi L, Puca R, Sacchi A, D'Orazi G, Mol Cancer 2009 8 1 10.1186/1476-4598-8-1 19128456
64. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP, Mol Cancer Ther 2007 6 1089 1098 10.1158/1535-7163.MCT-06-0663 17363502 (Pubitemid 46554580)
65. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Fabbri M, Garzon R, Cimmino A, et al. Proc Natl Acad Sci USA 2007 104 15805 15810 10.1073/pnas.0707628104 17890317 (Pubitemid 350035380)
66. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA. Klein ME, Lioy DT, Ma L, Lmpey S, Mandel G, Goodman RH, Nat Neurosci 2007 10 1513 1514 10.1038/nn2010 17994015 (Pubitemid 350175879)
67. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Nies AT, Jedlitschky G, Konig J, et al. Neuroscience 2004 129 349 360 10.1016/j.neuroscience.2004.07.051 15501592 (Pubitemid 39388854)
68. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Garofalo M, Di Leva G, Romano G, et al. Cancer Cell 2009 16 498 509 10.1016/j.ccr.2009.10.014 19962668
69. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Vinciguerra M, Sgroi A, Veyrat-Durebex C, Rubbia-Brandt L, Buhler LH, Foti M, Hepatology 2009 49 1176 1184 10.1002/hep.22737 19072831
70. Human polymorphism at microRNAs and microRNA target sites. Saunders MA, Liang H, Li WH, Proc Natl Acad Sci USA 2007 104 3300 3305 10.1073/pnas. 0611347104 17360642 (Pubitemid 46364154)
71. Pharmacogenomics of microRNA: a miRSNP towards individualized therapy. Bertino JR, Banerjee D, Mishra PJ, Pharmacogenomics 2007 8 1625 1627 10.2217/14622416.8.12.1625 18085993
72. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell. Mishra PJ, Banerjee D, Bertino JR, Cell Cycle 2008 7 853 858 10.4161/cc.7.7.5666 18414050 (Pubitemid 351573776)
73. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Yanaihara N, Caplen N, Bowman E, et al. Cancer Cell 2006 9 189 198 10.1016/j.ccr.2006.01.025 16530703 (Pubitemid 43357945)
74. Circulating microRNAs as stable blood-based markers for cancer detection. Mitchell PS, Parkin RK, Kroh EM, et al. Proc Natl Acad Sci USA 2008 105 10513 10518 10.1073/pnas.0804549105 18663219
75. High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Jansen MP, Reijm EA, Sieuwerts AM, Ruigrok-Ritstier K, Look MP, Rodriguez-Gonzalez FG, Heine AA, Martens JW, et al. Breast Cancer Res Treat 2012 133 937 947 10.1007/s10549-011-1877-4 22094936
76. Non-coding microRNAs hsa-let-7 g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M, Ju J, Cancer Genomics Proteomics 2006 3 317 324 18172508 (Pubitemid 44701551)
77. Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J, Mol Cancer 2010 9 96 10.1186/1476-4598-9-96 20433742
78. Specific alterations of microRNA transcriptome and global network structure in colorectal carcinoma after cetuximab treatment. Ragusa M, Majorana A, Statello L, Maugeri M, Salito L, Barbagallo D, Guglielmino MR, Duro LR, Angelica R, Caltabiano R, Biondi A, Di Vita M, Privitera G, et al. Mol Cancer Ther 2010 9 3396 3409 10.1158/1535-7163.MCT-10-0137 20881268
79. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. Mekenkamp LJ, Tol J, Dijkstra JR, de Krijger I, et al. BMC Cancer 2012 12 292 10.1186/1471-2407-12-292 22804917
80. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Zhang W, Zhang J, Yan W, You G, Bao Z, Li S, et al. Cancer 2013 119 814 824 10.1002/cncr.27826 22990979
81. MicroRNA expression, survival, and response to interferon in liver cancer. Ji J, Shi J, Budhu A, et al. N Eng J Med 2009 361 1437 1447 10.1056/NEJMoa0901282
82. MiRNA-21: a biomarker predictive of platinum-based adjuvant chemotherapy response in patients with non-small cell lung cancer. Gao W, Lu X, Liu L, Xu J, Feng D, Shu Y, Cancer Biol Ther 2012 13 330 340 10.4161/cbt.19073 22237007
83. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Weiss GJ, Bemis LT, Nakajima E, et al. Ann Oncol 2008 19 1053 1059 10.1093/annonc/mdn006 18304967 (Pubitemid 351796329)
84. MicroRNA microarray identifies let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Yang N, Kaur S, Volinia S, et al. Cancer Res 2008 68 10307 10314 10.1158/0008-5472.CAN-08-1954 19074899
85. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. Hwang JH, Voortman J, Giovannetti E, et al. PLoS One 2010 5 10630 10.1371/journal.pone.0010630 20498843
86. MicroRNA-21in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Giovannetti E, Funel N, Peters GJ, et al. Cancer Res 2010 70 4528 4538 10.1158/0008-5472.CAN-09-4467 20460539
87. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Preis M, Gardner TB, Gordon SR, Pipas JM, et al. Clin Cancer Res 2011 17 5812 5821 10.1158/1078-0432.CCR-11- 0695 21652542
88. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Arroyo JD, Chevillet JR, Kroh EM, et al. Proc Natl Acad Sci USA 2011 108 5003 5008 10.1073/pnas.1019055108 21383194
89. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT, Nat Cell Biol 2011 13 423 433 10.1038/ncb2210 21423178
90. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. Gallo A, Tandon M, Alevizos I, Illei GG, PLoS ONE 2012 7 30679 10.1371/journal.pone.0030679 22427800
91. Circulating miR-125b as a marker predicting chemoresistance in breast cancer. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, et al. PLoS ONE 2012 7 34210 10.1371/journal.pone.0034210 22523546
92. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC Jr, Park ST, Pusztai L, Calin GA, Cancer 2012 118 2603 2614 10.1002/cncr.26565 22370716
93. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Gut 2009 58 1375 1381 10.1136/gut.2008.167817 19201770
94. Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first line oxaliplatin-based treatment. Kjersem JB, Ikdahl T, Lingjaerde OC, Guren T, Tveit KM, Kure EH, Mol Oncol 2013 doi: 10.1016/j.molonc.2013.09.001
95. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Wei J, Gao W, Zhu C, Liu YQ, Mei Z, Cheng T, et al. Chin J Cancer 2011 30 407 414 10.5732/cjc.010.10522 21627863
96. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. Ohyashiki K, Umezu T, Yoshizawa S, Ito Y, Ohyashiki M, Kawashima H, et al. PLoS ONE 2011 6 16408 10.1371/journal.pone.0016408 21383985
97. Fludarabine treatment favors the retention of miR-485-3p by prostate cancer cells: implications for survival. Lucotti S, Rainaldi G, Evangelista M, Rizzo M, Mol Cancer 2013 12 52 10.1186/1476-4598-12-52 23734815
98. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, et al. Prostate 2011 71 326 331 10.1002/pros.21246 20842666
99. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Gamez-Pozo A, Anton-Aparicio LM, Bayona C, Borrega P, Gallegos Sancho MI, Garcia-Dominguez R, et al. Neoplasia 2012 14 1144 1152 23308047
100. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Madhavan D, Zucknick M, Wallwiener M, et al. Clin Cancer Res 2012 18 5972 5982 10.1158/1078-0432.CCR-12- 1407 22952344
101. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. Hu Z, Chen X, Zhao Y, et al. J Clin Oncol 2010 28 1721 1726 10.1200/JCO.2009.24.9342 20194856
102. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. Xi Y, Nakajima G, Gavin E, et al. RNA 2007 13 1668 1674 10.1261/rna.642907 17698639 (Pubitemid 47481675)
103. RNAi: nature abhors a double-strand. Hutvagner G, Zamore PD, Curr Opin Genet Dev 2002 12 225 232 10.1016/S0959-437X(02)00290-3 11893497 (Pubitemid 34219496)
104. Silencing of microRNAs in vivo with 'antagomirs'. Krutzfeldt J, Rajewsky N, Braich R, et al. Nature 2005 438 685 689 10.1038/nature04303 16258535 (Pubitemid 41740580)
105. Antagonism of microRNA-122 in mice by systematically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Elmen J, Lindow M, Silahtaroglu A, et al. Nucleic Acids Res 2008 36 1153 1162 18158304 (Pubitemid 351330933)
106. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Dickins RA, Hamann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Nat Genet 2005 37 1289 1295 16200064 (Pubitemid 41568715)
107. Synthetic microRNA and double-strand RNA targeting the 30-untranslated region of HER-2/neu mRNA inhibit HER-2 protein expression in ovarian cancer cells. Tsuda N, Kawano K, Efferson CL, Ioannides CG, Int J Oncol 2005 27 1299 1306 16211225
108. Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Liang Z, Wu H, Reddy S, Zhu A, Wang S, Blevins D, Biochem Biophys Res Commun 2007 363 542 546 10.1016/j.bbrc.2007.09. 007 17889832 (Pubitemid 47513664)
109. Targeted expression of mir-34a using the t-visa system suppresses breast cancer cell growth and invasion. Li L, Xie X, Luo J, Liu M, Xi S, Guo J, Kong Y, Wu M, Gao J, Xie Z, et al. Mol Ther 2012 20 2326 2334 10.1038/mt.2012.201 23032974
110. Over-expression of mir-145 enhances the effectiveness of hsvtk gene therapy for malignant glioma. Lee SJ, Kim SJ, Seo HH, Shin SP, Kim D, Park CS, Kim KT, Kim YH, Jeong JS, Kim IH, Cancer Lett 2012 320 72 80 10.1016/j.canlet.2012.01.029 22269208
111. Adenovirus-mediated shrnas for co-repression of mir-221 and mir-222 expression and function in glioblastoma cells. Wang X, Han L, Zhang A, Wang G, Jia Z, Yang Y, Yue X, Pu P, Shen C, Kang C, Oncol Rep 2011 25 97 105 21109963
112. Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforma cells conferred chemosensitivity. Munoz JL, Bliss SA, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P, Mol Ther Nucleic Acids 2013 2 126 10.1038/mtna.2013.60 24084846
113. Therapeutic microrna delivery suppresses tumorigenesis in a murine liver cancer model. Kota J, Chivukula RR, Odonnell KA, Wentzel EA, Montagomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, et al. Cell 2009 137 1005 1017 10.1016/j.cell.2009.04.021 19524505
114. Regression of murine lung tumors by the let-7 microrna. Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, et al. Oncogene 2010 29 1580 1587 10.1038/onc.2009.445 19966857
115. Systemic delivery of tumor suppressor microrna mimics using a neutral lipid emulsion inhibits lung tumors in mice. Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ, Mol Ther 2011 19 1116 1122 10.1038/mt.2011.48 21427705
116. Nanoparticle-based therapy in an in vivo microrna-155 (mir-155)-dependent mouse model of lymphoma. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ, Proc Natl Acad Sci USA 2012 109 1695 E1704 10.1073/pnas.1201516109 22685206
117. Silencing of the miR-17 92 cluster family inhibits medulloblastoma progression. Murphy BL, Obad S, Bihannic L, Ayrault O, Zindy F, Kauppinen S, Roussel MF, Cancer Res 2013 73 7068 7078 10.1158/0008-5472.CAN-13-0927 24145352
118. Targeting miR-21 for the therapy of pancreatic cancer. Sicard F, Gayral M, Lulka H, Buscail L, Cordelier P, Mol Ther 2013 21 986 994 10.1038/mt.2013.35 23481326
119. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Medina PP, Nolde M, Slack FJ, Nature 2010 467 86 90 10.1038/nature09284 20693987
120. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Meng F, Henson R, Lang M, et al. Gastroenterology 2006 130 2113 2129 10.1053/j.gastro.2006.02.057 16762633 (Pubitemid 43816961)
121. MicroRNA-21 inhibition enhances in vitro chemosensitivity of temozolomide-resistant glioblastoma cells. Wong ST, Zhang XQ, Zhuang JT, Chan HL, Li CH, Leung GK, Anticancer Res 2012 32 2835 2841 22753745
122. MiR-92b regulates the cell growth, cisplatin chemosensitivity of A549 non small cell lung cancer cell line and target PTEN. Li Y, Li L, Guan Y, Liu X, Meng Q, Guo Q, Biochem Biophys Res Commun 2013 440 604 610 10.1016/j.bbrc.2013. 09.111 24099768
123. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Weidhaas JB, Babar I, Nallur SM, et al. Cancer Res 2007 67 11111 11116 10.1158/0008-5472.CAN-07-2858 18056433 (Pubitemid 350248533)
124. MicroRNA-21: a novel therapeutic target in human cancer. Pan X, Wang ZX, Wang R, Cancer Biol Ther 2011 10 1224 1232
125. Causes and consequences of microRNA dysregulation. Iorio MV, Croce CM, Cancer J 2012 18 215 222 10.1097/PPO.0b013e318250c001 22647357
126. MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines. Rodrigues AC, Li X, Radecki L, et al. Biopharm Drug Dispos 2011 32 355 367 10.1002/bdd.764 21796641
127. A small molecule enhances RNA interference and promotes microRNA processing. Shan G, Li Y, Zhang J, et al. Nature Biotech 2008 26 933 940 10.1038/nbt.1481
128. The small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Melo S, Villanueva A, Moutinho C, et al. Proc Natl Acad Sci USA 2011 108 4394 4399 10.1073/pnas.1014720108 21368194
129. Rapid alteration of microRNA levels by histone deacetylase inhibition. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC, Cancer Res 2006 66 1277 1281 10.1158/0008-5472.CAN-05-3632 16452179 (Pubitemid 43259904)
130. SM2miR: a database of the experimentally validated small molecules's effects on microRNA expression. Liu X, Wang S, Meng F, et al. Bioinformatives 2013 29 409 411 10.1093/bioinformatics/bts698
131. Targeting microRNAs with small molecules: from dream to reality. Zhang S, Chen L, Jung EJ, Calin GA, Clin Pharmacol Ther 2010 87 754 758 10.1038/clpt.2010.46 20428111
132. Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses. Jiang W, Chen Z, Liao M, Li W, et al. Sci Rep 2012 2 282 22355792
133. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Grimm D, Streetz KL, Jopling CL, et al. Nature 2006 441 537 541 10.1038/nature04791 16724069 (Pubitemid 44050158)